Disc Medicine files $189.9 million stock offering after APOLLO Phase 3 win in EPPNov 5FinancingbitopertinDisc Medicine, IncUpdated
Disc Medicine prices offering at 6 million shares, raising about $450 millionOct 21FinancingbitopertinDisc Medicine, IncUpdated
Disc Medicine says bitopertin hit all endpoints in Phase 3 APOLLO trial for EPPOct 19Clinical readoutbitopertinDisc Medicine, Inc
Disc Medicine reports Q2 2026 results, aligns with FDA on bitopertin path in EPPJul 30Quarterly updatebitopertinDisc Medicine, Inc